Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisAbacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsHIV infection and cardiovascular diseaseDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseEffects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Cardiovascular disease in HIV patients: from bench to bedside and backwards.Antiretroviral therapy: when to startEpidemiology and management of antiretroviral-associated cardiovascular disease.Clinical outcomes of a combined HIV and renal clinic.Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseIs there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.HIV infection and stroke: current perspectives and future directionsAbacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimensInflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events.HIV stroke risk: evidence and implications.Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral RegimensInflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.Pathophysiology and management of cardiovascular disease in patients with HIVMaraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot StudyA review of the toxicity of HIV medications.Cardiovascular disease and HIV infection.Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.
P2860
Q21999480-9394CC71-61A1-4613-B6DA-91DA5A0358B8Q24202180-965D414B-FD6B-4180-B338-6363BCD07F2EQ26768591-C23817A5-9566-45D5-96A2-EAE025D5E687Q27008915-4132FAD0-CC64-4B8A-ACD1-3F3E732B9133Q28543075-ACCE3A58-5A5E-4D6D-BEC3-A73680B0144EQ28543212-E2EC825C-BC9D-40B7-BC6F-0AC85B2541A1Q30248286-F8AC020F-A9BA-4A30-8EFE-10D25ED8BBD5Q31118978-563A7B1A-149B-43DD-95C4-234DAEFB459EQ33595432-942DEDF4-52EC-42A8-A616-0A8ABEB58A09Q33649200-81A5E089-7C8E-4E07-A661-16116354EA87Q33841718-1F880A1D-EAFD-46BF-824E-4B026F0AB8C7Q34077477-4A2A1234-6AC0-4569-8465-2BBFDAE548BAQ34157856-7D86ECB1-2212-4045-BC87-FC31404F02B9Q34736194-10F45C28-8E4C-4365-A7F9-73D9EDEE63F2Q35203971-BD75E61F-734D-4A9A-8B5B-069E532C7A93Q35204279-04AAD7E6-8AB5-49C3-9F20-2C8131B0E6BFQ35338096-AD6ECDEC-F248-4E23-BD33-8B5F4A66D83EQ35453074-B5C986CE-5B81-400B-8B00-534524C090E6Q35737682-39F6DB7B-0607-4EA7-BE3D-D30A71B3297BQ35977313-D5B114E3-4E4F-478F-ACFD-62EA2631E5D8Q36116238-050C07BA-3A08-4ADB-BCEE-4DA0C236B439Q36137160-B8D88795-A734-4D95-A6CC-34F2EFF90BD4Q36285922-28DB1D8A-134A-4B16-8FB8-C9BB9A6D4195Q36404094-72F5675E-438A-453F-9CE8-CD6BD3F85D1BQ36419549-26A6D9BE-E6DD-4113-ADCF-FDC3C8E77B82Q36578046-6304D6A2-5130-4855-AEC9-D3DAAED1C720Q36628328-8754AA50-E027-4697-8FE6-DFE61098BA3CQ36722756-6600C323-AB16-4E14-A91F-3F03C55F1CFCQ36844074-0B0E35C7-AE25-477D-8E37-34FE2CC15E48Q36899983-D792929A-2AE9-490A-BE65-70FB9506BA80Q36974022-139F9D4D-2EBD-4BE0-B5E3-175AAB2E05B8Q37038775-872695D7-2CE7-49E3-98B5-67D354924DE6Q37250180-491368AB-2798-457C-AE6C-B69664911226Q37633495-732E75EF-685C-483A-A78B-DE74726DC868Q37661603-7180811E-E1C3-4014-A8F5-CE99DE1349D8Q37665526-341CABF9-8441-4986-8687-D1BB3B1151D8Q37993138-4AAECB67-F9A5-4B27-B1B6-8156A799A97EQ38021848-5F5C28D3-A8BF-4F92-9230-07D3DBE859F9Q38023235-12A22CA7-E92F-47E9-AF3A-F0F942A761CEQ38111430-BC372482-EA77-43F0-A2CA-3D3D7C41F424
P2860
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Abacavir use and cardiovascula ...... ublished and unpublished data.
@ast
Abacavir use and cardiovascula ...... ublished and unpublished data.
@en
type
label
Abacavir use and cardiovascula ...... ublished and unpublished data.
@ast
Abacavir use and cardiovascula ...... ublished and unpublished data.
@en
prefLabel
Abacavir use and cardiovascula ...... ublished and unpublished data.
@ast
Abacavir use and cardiovascula ...... ublished and unpublished data.
@en
P2093
P1433
P1476
Abacavir use and cardiovascula ...... ublished and unpublished data.
@en
P2093
Giovanni Serpelloni
Graeme Moyle
Marina Malena
Mario Cruciani
Oliviero Bosco
Romualdo Mazzi
Saverio G Parisi
Veronica Zanichelli
P304
P356
10.1097/QAD.0B013E328349C6EE
P407
P577
2011-10-01T00:00:00Z